Security key
604749101
Mirum Pharmaceuticals, Inc. - Common Stock (MIRM)
CUSIP: 604749101
Q3 2024 13F Holders as of 30 Sep 2024
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 53,301,609
- Total 13F value
- $2,079,251,226
- Share change
- -191,595
- Put/Call ratio
- 94%
- SEC-reported price per share
- $39.00
- Number of holders
- 176
- Value change
- -$2,890,149
- Number of buys
- 108
- Number of sells
- 57
- Shares outstanding
- 60,799,281
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2024
Institutions
176
Top holders
10
MIRM full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Mirum Pharmaceuticals, Inc. SEC filings
Mirum Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 604749101
Recent filing periods:
Ownership snapshot
Top reported holders of MIRM - Mirum Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Frazier Life Sciences Man...
Disclosed value leader
Frazier Life Sciences Man...
Comparable rows
15/15
Latest evidence
30 Jun 2024
13F
Lead comparable stake: 11%
Showing 1-6 of 15 holder rows.
Quick read
Frazier Life Sciences Management, L.P. leads the comparable SEC ownership view at 11%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Frazier Life Sciences Management, L.P.'s linked filing trail.
Comparable ownership
Top 5
Frazier Life Sciences Management,...
11%
Janus Henderson Group Ltd.
8.2%
BVF INC/IL
7.2%
EVENTIDE ASSET MANAGEMENT, LLC
5.9%
BlackRock Finance, Inc.
5.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. |
13F
Company
|
11%
|
$222,077,452
6,495,392 shares
|
— | 30 Jun 2024 |
| Janus Henderson Group Ltd. |
13F
Company
|
8.2%
|
$170,557,599
4,988,747 shares
|
— | 30 Jun 2024 |
| BVF INC/IL |
13F
Company
|
7.2%
|
$149,411,121
4,370,024 shares
|
— | 30 Jun 2024 |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
Company
|
5.9%
|
$123,590,696
3,614,820 shares
|
— | 30 Jun 2024 |
| BlackRock Finance, Inc. |
13F
Company
|
5.3%
|
$110,708,894
3,238,049 shares
|
— | 30 Jun 2024 |
| VANGUARD GROUP INC |
13F
Company
|
4%
|
$83,653,801
2,446,733 shares
|
— | 30 Jun 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
176
Shares
53,301,609
Rows available
176
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2024 vs Q2 2024 Across Filers
Q2 2024 holders
157
Q3 2024 holders
176
Holder diff
19
| Investor | Q2 2024 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q2 2024 value | Q3 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend